Acute Kidney Injury After Intensive Blood Pressure Lowering Following Successful Endovascular Thrombectomy.

StrokeJul 24, 2026 (epub)
Clinical ResearchNephrologyNeurologyInternal Medicine (General)

Jae Wook Jung, Hee Byung Koh, Young Dae Kim et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial analyzed the impact of intensive blood pressure management on acute kidney injury (AKI) in 287 patients with acute ischemic stroke post-endovascular thrombectomy. The study found that AKI within 7 days occurred more frequently in the intensive management group (13.6%) compared to the conventional group (6.4%), with an adjusted odds ratio of 2.54.

Key findings

  • AKI within 7 days was more frequent in the intensive group (13.6%) than in the conventional group (6.4%).
  • Patients with AKI had significantly lower rates of functional independence (13.8% vs 49.0%).
  • AKI was associated with higher stroke-related mortality at 3 months (37.9% vs 3.1%).

Why it matters

The findings highlight the potential risks associated with aggressive blood pressure management in stroke patients, particularly regarding kidney function and long-term outcomes. Understanding these risks is crucial for optimizing post-thrombectomy care.

Source

PubMed · PMID 42495732

Published in Stroke. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nephrology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.